Osteonecrose dos maxilares relacionada ao uso de medicações: Diagnóstico, tratamento e prevenção

Lidia Nunes Vilela-Carvalho, Nathália Tuany-Duarte, Marília Andrade-Figueiredo, Karem López-Ortega

Resumen


A osteonecrose dos maxilares é uma alteração óssea que pode ser induzidapelo uso de drogas indicadas para o tratamento de pacientes comosteoporose e tumores malignos. Inicialmente acreditava-se estar associadaapenas ao uso de bisfosfonatos, atualmente sabe-se que tambémestá vinculada ao uso de outro antirresorptivo (denosumabe) e de antiangiogênico(bevacizumabe). Não se sabe ao certo qual é o mecanismo dedesenvolvimento e ainda não existe um protocolo único de tratamento definido,mas existem diversos trabalhos sendo publicados sobre o tema.Com a crescente quantidade de casos relatados é de suma importânciaque o profissional de saúde saiba diagnosticar, identificar os riscos e trataressa condição.

 

Medication-Related Osteonecrosis of the Jaw: Diagnosis,treatment and prevention

Osteonecrosis of the jaws is a bone alteration that can be induced usingdrugs indicated for the treatment of patients with osteoporosis and malignanttumors. Initially it was believed to be associated only with the useof bisphosphonates, currently it is known that it is also linked to the use ofother antiresorptive (denosumab) and antiangiogenic (bevacizumab). It isnot known what the development mechanism is and there is still no singledefined treatment protocol, but there are several papers being published on the topic. With the increasing number of cases reported, it is extremely importantthat the health professional can diagnose, identify the risks and treat this condition.

Keywords: Osteonecrosis of the jaws, Bisphosphonates, Denosumab, Bevacizumab.

 

Osteonecrosis de los maxilares relacionados con el uso demedicamentos: Diagnóstico, tratamiento y prevención

La osteonecrosis de los maxilares es una alteración ósea que puede ser inducidapor el uso de drogas indicadas para el tratamiento de pacientes con osteoporosis ytumores malignos. Inicialmente se creía estar asociada sólo al uso de bisfosfonatos,actualmente se sabe que también está vinculada al uso de otro antirresorptivo (denosumab)y de antiangiogénico (bevacizumabe). No se sabe con certeza cuál es elmecanismo de desarrollo y aún no existe un protocolo único de tratamiento definido,pero existen diversos trabajos siendo publicados sobre el tema. Con la crecientecantidad de casos reportados es de suma importancia que el profesional de saludpueda diagnosticar, identificar los riesgos y tratar esa condición.

Palabras clave: Osteonecrosis de los maxilares, Bisfosfonatos, Denosumab, Bevacizumab.


Palabras clave


Osteonecrose dos maxilares, Bisfosfonatos, Denosumabe, Bevacizumabe.

Texto completo:

PDF

Referencias


- Almazrooa SA, Woo SB. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc 2009;140(7):864-75.

- Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010;95(4):1555-65.

- Marx RE. Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxilofac Surg 2003; 61(9):1115-7.

- Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG. The relationship between the chemistry and biological activity of the bisphosphonates. Bone. 2011 Jul;49(1):20-33.

- Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral

Maxillofac Surg 2004;62(5):527-34.

- Hohnecker JA. Dear Doctor. Precautions Added to the Label of Aredia and Zometa. Novartis Oncology, East Hanover, NJ; 2004:2. Available from:

http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B2_02_10-Novartis-Zometa-App-9.pdf

- Estilo CI, Fornier M, Farooki A, Carrlson D, Bohle G, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008;26(24):4037-8.

- Sivolella S, Lumachi F, Stellini E, Favero L. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease. Anticancer Res 2013;33(5):1793-7.

- Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg 2013;71(9):1532-40.

- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72(10):1938-56.

- Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F et al. International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015;30(1):3-23.

- Zhang X, Hamadeh IS, Song S, Lesko LJ, Gong Y. Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). J Bone Miner Res 2015 Aug 19. doi: 10.1002/jbmr.2693. [Epub ahead of print]

- Hellstein J. Osteochemonecrosis: an overview. Head Neck Pathol 2014;8(4):482-90

- Mondello P, Pitini V, Arrigo C, Mondello S, Mian M, Altavilla G. Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. Springerplus 2014;5;3:123. doi: 10.1186/2193-1801-3-123. eCollection 2014

- Hamadeh IS, Ngwa BA, Gong Y. Drug induced osteonecrosis of the jaw. Cancer Treat Rev 2015;41(5):455-64.

- Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrota B. American association of oral and maxillofacial surgeons position paper on biphosphonate-related osteonecrosis of the jaws – 2009 update. J Oral Maxillofac Surg 2009; 67(5suppl): 2-12.

- Palaska PK, Cartsos V, Zavras AI. Bisphosphonates and time to osteonecrosis development. Oncologist 2009;14(11):1154-66.

- Katz J, Gong Y, Salmasinia D, Hou W, Burkley B, Ferreira P et al. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int J Oral Maxillofac Surg 2011;40(6):605-11.

- Nicoletti P, Cartsos VM, Palaska PK, Shen Y, Floratos A, Zavras AI. Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist 2012;17(2):279-87.

- Kim JH, Ko YJ, Kim JY,Oh Y, Hwang J, Hab S et al. Genetic investigation of bisphosphonate-related osteonecrosis of jaw (BRONJ) via whole exome sequencing and bioinformatics. PLoS One 2015;10:e0118084. doi: 10.1371/journal.pone.0118084. eCollection 2015

- Cheung A, Seeman E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 2010;363(25):2473-4.

- Pelaz A, Junquera L, Gallego L, García-Consuegra L, Junquera S, Gómez C. Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: a pilot study comparing fibrin rich in growth factors and teriparatide. Med Oral Patol Oral Cir Bucal 2014;19(4):e320-6.

- Ohbayashi Y, Miyake M, Sawai F, Minami Y, Iwasaki A, Matsui Y. Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115:e31-7.

- Fleisher KE, Welch G, Kottal S, Craig RG, Saxena D, Glickman RS. Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110(4):509-16.

- Bodem JP, Kargus S, Engel M, Hoffmann J, Freudlsperger C. Value of nonsurgical therapeutic management of stage I bisphosphonate-related osteonecrosis of the jaw. J Craniomaxillofac Surg 2015;43(7):1139-43.

- Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P et al. A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol 2014;50(11):1049-57.

- Vescovi P, Giovannacci I, Merigo E, Meleti M, Manfredi M, Fornaini C et al. Tooth extractions in high-risk patients under bisphosphonate therapy and previously affected with osteonecrosis of the jaws: surgical protocol supported by low-level laser therapy. J Craniofac Surg 2015;26(3):696-9.

- Vescovi P, Meleti M, Merigo E, Manfredi M, Fornaini C, Guidotti R et al. Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd:YAG low-level laser therapy. Med Oral Patol Oral Cir Bucal 2013;18(4):e680-5.

- Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S.

Bisphosphonates-related osteonecrosis of the jaws: a concise review of the

literature and a report of a single-centre experience with 151 patients. J Oral

Pathol Med 2012;41(3):214-21.

– Blus C, Szmukler-Moncler S, Giannelli G, Denotti G, Orrù G. Use of Ultrasonic Bone Surgery (Piezosurgery) to Surgically Treat Bisphosphonate-Related Osteonecrosis of the Jaws (BRONJ). A Case Series Report with at Least 1 Year of Follow-Up. Open Dent J 2013;7:94-101.

- Atalay B, Yalcin S, Emes Y, Aybar B, Issever H, Mandel NM et al. Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery? Lasers Med Sci 2011;26(6):815-23.

- Rugani P, Truschnegg A, Acham S, Kirn-bauer B, Jakse N. Use of photodynamic therapy in treatment of bisphosphonate-related osteonecrosis of the jaws: literature review and case series. J Anal Bioanal Tech 2013;S1:006. doi: 10.4172/2155-9872.S1-006

– Pautke C, Bauer F, Otto S, Tischer T, Steiner T, Weitz J et al. Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study. J Oral Maxillofac Surg 2011;69(1):84-91.

- Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg 2015;44(5):568-85.

- Freiberger JJ, Padilla-Burgos R, McGraw T, Suliman HB, Kraft KH, Stolp BW et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Oral Maxillofac Surg 2012;70(7):1573-83.

- Agrillo A, Filiaci F, Ramieri V,Riccardi E, Quarato D, Rinna C et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy. Eur Rev Med Pharmacol Sci 2012;16(12):1741-7.

- Hinchy NV, Jayaprakash V, Rossitto RA, Anders PL, Korff KC, Canallatos P et al. Osteonecrosis of the jaw - prevention and treatment strategies for oral health professionals. Oral Oncol 2013;49(9):878-86.

- Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Kokas S et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2011;142(11):1243-51.

- Damm DD, Jones DM. Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. Gen Dent 2013;61(5):33-8

– Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, et al; International Task Force on Osteonecrosis of the Jaw. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom. 2017 Jan - Mar;20(1):8-24.

- ANVISA. Informe SNVS/Anvisa/Nuvig/GFARM nº 07, de 09 de outubro de 2013. Associação entre uso de bifosfonatos e ocorrência de osteonecrose mandibular. Available from: http://portal.anvisa.gov.br/wps/wcm/connect/31613e0041657bc98cddacf92fe288f3/Informe+n%C2%BA+072013+Bifosfonatos+08102013.pdf?MOD=AJPERES. Acessado em 20/08/2015.

- Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A et al. Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. Br J Oral Maxillofac Surg 2015;53(1):13-7.

- Kim DW, Jung YS, Park HS, Jung HD. Osteonecrosis of the jaw related to everolimus: a case report. Br J Oral Maxillofac Surg 2013;51(8):e302-4.




Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

 

 

CES Odontología/ ISSN 0120-971X Electrónico 2215-9185

Facultad de Odontología, Universidad CES.

Calle 10A No. 22 - 04, Medellín, Colombia

Publicada desde 1987.

revistaodontologia@ces.edu.co

 

http://www.ces.edu.co/